ETF Coverage: ProShares UltraPro Short Nasdaq Biotech (ZBIO) Rises 6.66% for Nov 30

November 30, 2016 - By Adrian Mccoy   ·   0 Comments

Nov 30 is a positive day so far for ProShares UltraPro Short Nasdaq Biotech (NASDAQ:ZBIO) as the ETF is active during the day after gaining 6.66% to hit $22.1 per share. The exchange traded fund has 7.25M net assets and 6.78% volatility this month.

Over the course of the day 154,191 shares traded hands, as compared to an average volume of 78,420 over the last 30 days for ProShares UltraPro Short Nasdaq Biotech (NASDAQ:ZBIO).

The ETF is -62.02% of its 52-Week High and 7.14% of its low, and is currently having ATR of 2.23. This year’s performance is -5.66% while this quarter’s performance is -6.75%.

The ETF’s YTD performance is 43.98%, the 1 year is 19.85% and the 3 year is NaN%.

The fund’s top holdings are: Nasdaq Biotechnology Index Swap Societe Generale for 149.15% of assets, Nasdaq Biotechnology Index Swap Goldman Sachs International for 83.44%, Nasdaq Biotechnology Index Swap Bank Of America Na for 56.48%, Nasdaq Biotechnology Index Swap Deutsche Bank Ag for 9.02%, Nasdaq Biotechnology Index Swap Ubs Ag for 1.90%.

More notable recent ProShares UltraPro Short NASDAQ Biotechnology (NASDAQ:ZBIO) news were published by: Marketwatch.com which released: “ProShares UltraPro Short NASDAQ Biotechnology” on March 08, 2014, also Etftrends.com with their article: “Biotech ETFs Still in Fragile Spots” published on November 25, 2016, Benzinga.com published: “ProShares Releases 2 New Leveraged Biotech ETFs” on June 23, 2015. More interesting news about ProShares UltraPro Short NASDAQ Biotechnology (NASDAQ:ZBIO) were released by: Etftrends.com and their article: “As Election Day Arrives, Is It Finally Time to Buy Biotech ETFs?” published on November 08, 2016 as well as Etftrends.com‘s news article titled: “Finally A Biotech ETF Bounce?” with publication date: June 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>